Literature DB >> 2834542

Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells.

V C Yu1, W Sadée.   

Abstract

Upon differentiation with retinoic acid of the human neuroblastoma cells SH-SY5Y into mature neurons, opioid drugs become highly effective in suppressing prostaglandin E1 (50% inhibition)- and forskolin (70% inhibition)-stimulated adenylate cyclase activity, which was assessed by measuring cyclic AMP accumulation in intact cells. Whereas the SH-SY5Y cells carry both mu and delta receptors in a ratio of mu/delta approximately equal to 5/1, the response is predominantly mediated by the mu receptor. Morphine acts as a strong agonist with an EC50 of 50 to 100 nM which falls into the therapeutic range expected for narcotic analgesic effects mediated by the mu receptor. Narcotic analgesic drugs with only partial agonism fail to evoke full response, which suggests that this cell model could provide a rapid screening assay for narcotic analgesic efficacy. Continued exposure of the cells to morphine resulted in partial tolerance within 12 hr with a 4-fold shift of morphine's EC50 to higher concentrations, whereas longer morphine exposure did not cause any further shift. Thus, the differentiated SH-SY5Y cells provide a suitable system for studying the molecular mechanisms of the narcotic analgesics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834542

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

Review 2.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

3.  Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists.

Authors:  P A Claude; D R Wotta; X H Zhang; P L Prather; T M McGinn; L J Erickson; H H Loh; P Y Law
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 4.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

5.  Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy mu-opioids.

Authors:  H Ammer; R Schulz
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

6.  Pharmacological examination of contractile responses of the guinea-pig isolated ileum produced by mu-opioid receptor antagonists in the presence of, and following exposure to, morphine.

Authors:  M K Mundey; A Ali; R Mason; V G Wilson
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

7.  μ-Opioid receptor coupling to Gα(o) plays an important role in opioid antinociception.

Authors:  Jennifer T Lamberts; Emily M Jutkiewicz; Richard M Mortensen; John R Traynor
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

8.  Mu-opioid signaling modulates biphasic expression of TrkB and IκBα genes and neurite outgrowth in differentiating and differentiated human neuroblastoma cells.

Authors:  Aiyun Wen; Abra Guo; Yulong L Chen
Journal:  Biochem Biophys Res Commun       Date:  2013-02-16       Impact factor: 3.575

Review 9.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

10.  Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain.

Authors:  B D Carter; F Medzihradsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.